Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples